MONTREAL, May 25, 2011 /CNW Telbec/ - Advanomics Corporation, the parent
company of Sunshine Biopharma Inc. (OTCBB Symbol: SBFM), is pleased to
announce that it has recently received an RNA patent in Europe
(European Patent Number: 1709199). This patent positions Advanomics as
a leader in the hotly pursued and very lucrative field of RNA
research. Dr. Steve N. Slilaty, the inventor on this important patent,
is the CEO of both Sunshine Biopharma and Advanomics Corporation. Dr.
Slilaty holds four other patents issued in the United States, Europe
and other countries around the world. Among Dr. Slilaty's other
scientific accomplishments is the discovery of a new class of proteases
called the S24 Family of Peptidases (IUBMB Enzyme Nomenclature: EC
Advanomics's new RNA patents relates to methodology for rapid
identification of all RNAs that can be made from any given piece of
DNA. With this unique capability Advanomics is able to compare RNA
profiles generated from Normal Tissue against Cancer Tissue and quickly
identify new cancer targets for therapeutic intervention.
Advanomics Corporation is ready to license this new patent to companies
interested in identifying therapeutically important RNAi molecules.
Advanomics Corporation is a privately held Canadian company focused on
the research, development and commercialization of drugs for the
treatment of various forms of cancer. Advanomics is conducting
research and development in the area of Carbon-Difluoride Chemistry to
generate novel anti-cancer compounds and in the area of RNA Technology
for deciphering genomic information and rapid identification of disease
related molecular targets for therapeutic intervention.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly
historical, including statements as to revenue projections, business
strategy, outlook, objectives, future milestones, plans, intentions,
goals, future financial conditions, future collaboration agreements,
the success of the Company's development, events conditioned on
stockholder or other approval, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.
SOURCE Sunshine Biopharma Inc.
For further information:
For licensing and additional information contact:
Mr. Camille Sebaaly
Tel: 514 764 9698
Fax: 514 764 9699
Direct: 514 814 0464